Are calcium antagonists proarrhythmic?

Journal of Hypertension

Volumn 15, Issue 9, 1997, Pages 915-923

  Bassett, Arthur L ^a   Chakko, Simon ^a   Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Calcium overload; Dyhydropyridines; L type Ca2+ channels; Reflex sympathetic activity; T type Ca2+ channels

Indexed keywords

CALCIUM; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CATECHOLAMINE; DILTIAZEM; NIFEDIPINE; VERAPAMIL;

BLOOD PRESSURE; CALCIUM CELL LEVEL; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0030864945     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715090-00001     Document Type: Review

References (50)

1. 1 Kassler KM: Recognition and management of cardiac arrhythmias. Curr Problems Cardiol 1995, 20:53-120.
2. Myerburg RJ, Kessler KM, Chakko S, Cox MM, Fernández P, Interian A, et al.: Future evaluation of antiarrhythmic therapy. Am Heart J 1994, 127:1111-1118.
3. Billman GE: The antiarrhythmic effects of calcium antagonists. In Calcium Antagonists in Clinical Medicine. Second Edition. Edited by Epstein M. Philadelphia, PA: Hanley & Belfus.; Inc.; 1997, in press.
4. Levy MM: Role of calcium in arrhythmogenesis. Circulation 1983, 80:IV23-IV30.
5. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raughunathan TE, Weiss NS, et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625.
6. Yusuf S: Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation 1995, 92: 1079-1082.
7. Buring JE, Glynn RJ, Hennekens CH: Calcium channel blockers and myocardial infarction. A hypothesis formulated but not tested. JAMA 1995, 274:654-655.
8. Epstein M: Calcium antagonists should continue to be used for first line treatment of hypertension. Arch Intern Med 1995, 155:2150-2156.
9. Epstein M: Calcium antagonists: still appropriate as first line antihypertensive agents Am J Hypertens 1996, 9:110-121.
10. Furberg C: Calcium antagonists: not appropriate as first line antihypertensive agents. Am J Hypertens 1996, 9:122-125.
11. Chinushi M, Aizawa Y, Miyajima S, Funazaki T, Tamura M, Shibata A: Proarrhythmic effects of antiarrhythmic drugs assessed by electrophysiologic study in recurrent sustained ventricular tachycardia. Jap Circ J 1991, 55:133-141.
12. 2 Saikawa T, Inoue K, Ohmura I, Ito S, Yonemochi H, Nakagawa M, et al.: The paradoxical adverse effect of verapamil for treating clinical paroxysmal supraventricular tachycardia. Jap Heart J 1987, 28:107-113.
13. 3 Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lamber G, Kaye DM, el at.: Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996, 93:1667-1676.
14. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, et al.: Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995, 92:3206-3211.
15. Michalewicz L, Messerli FH: Cardiac effects of calcium antagonists in hypertension. Am J Cardiol 1997, 79 (suppl 10A):39-46.
16. Chakko S, Bassett AL: The clinical antiarrhythmic effectiveness of calcium channel antagonists. In Calcium Antagonists in Clinical Medicine. Second Edition. Edited by Epstein M, Philadelphia: Hanley & Belfus, Inc.; 1997 (in press).
17. Leenen FHH: Calcium antagonists and sympathetic activity: relevance for cardiovascular morbidity and mortality. In Calcium Antagonists in Clinical Medicine. Second Edition. Edited by Epstein M. Philadelphia: Hanley & Belfus, Inc.; 1997, in press.
18. Grossman E, Messerli FH: Calcium antagonists and sympathetic activity. Am J Cardiol 1997, in press.
19. Morris AD, Meredith PA, Reid JL: Pharmacokinetics of calcium antagonists: implications for therapy. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley & Belfus, Inc.; 1992:1-27.
20. Triggle DJ: Biochemical and pharmacological differences among calcium antagonists: clinical implications. In Calcium Antagonists in Clinical Medicine. Second Edition., Philadelphia: Hanley & Belfus, Inc.; 1997, in press.
21. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting antagonists. In Hypertension, Diagnosis, and Management. Second Edition. Edited by Laragh JH. New York: Raven Press; 1995:2815-2825.
22. Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD, et al.: Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987, 41:26-30.
23. van Zwieten PA, Hansson L, Epstein M. Slowly acting calcium antagonists and their merits. Blood Pressure 1997, 6:78-80.
24. Messerli FH, Nuñez BD, Nuñez MM, Garavaglia GE, Schmieder RE, Ventura HO: Calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989, 149:1263-1267.
25. Vogt M, Strauer BE: Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Am J Cardiol 1995, 76:24D-3OD.
26. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996, 275: 1507-1513.
27. Campbell SE, Turek Z, Rakusan K, Kazda S: Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine and nisoldipine. Cardiovasc Res 1993, 27:1350-1358.
28. Suzuki M, Yamanaka K, Nabata H, Tachibana M: Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypertensive rats. Eur J Pharmacol 1993, 228: 269-274.
29. Nayler WG: The role of oxygen radicals during reperfusion. J Cardiovasc Pharmacol 1992, 20 (suppl 5):S14-S17.
30. Yusuf S: Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation 1995, 92:1079-1082.
31. Rome RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste K: Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. JAMA 1990, 264:3171-3177.
32. The Multicenter Diltiazem Post-Infarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988, 319:385-392.
33. Bigger JT, Coromilas J, Rolnitzky LM, Fleiss JL, Kleiger RE, and the Multicenter Diltiazem Post-Infarction Trial Investigators: Effect of diltiazem on cardiac rate and rhythm after myocardial infarction. Am J Cardiol 1990. 65:539-546.
34. Chakko S, de Marchena E, Kessler KM, Myerburg RJ: Ventricular arrhythmias in congestive heart failure. Clin Cardiol 1989, 12: 525-530.
35. Packer M, O'Conner CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. for the PRAISE Study Group: Effect of amlodipine on morbidity and mortality in chronic heart failure. N Engl J Med 1996, 335:1107-1114.
36. Braun S, Boyko V, Behar S, Reicher-Reiss H, Shotan A, Schlesinger Z, et al., on behalf of the Bezafibrate Infarction Prevention Study Participants: Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996, 28:7-11.
37. Kloner RA, Vetrovec G: Long acting calcium channel blockers nifedipine GITS and amlodipine in hypertension - rate of myocardial infarction [abstract]. J Am Coll Cardiol 1996, 27:177A.
38. Messerli FH: Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context Ann Intern Med 1995, 123:888-889.
39. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial H - DAVIT H). Am J Cardiol 1990, 66:779-785.
40. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, et al., and the Diltiazem Reinfarction Study Group: Diltiazem and reinfarction in patients with non-Q myocardial infarction: results of double-blind, randomized, multicenter trial. N Engl J Med 1986, 315:423-429.
41. Messerli FH, Boden WE, Fischer-Hansen J, Schechtman KB: Heart rate lowering calcium antagonists in hypertensive post-MI patients [abstract]. J Am Coll Cardiol 1996, 27:178A.
42. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ: Regulation and modulation of calcium channels in cardiac, skeletal and smooth muscle cells. Physiol Rev 1994, 74:365-507.
43. Tiaho F, Richard S, Lory P, Nerbonne JM, Nargeot J: Cyclic-AMP- dependent phosphosylation modulates the stereospecific activation of cardiac calcium channels by Bay 8649. Pllügers Arch 1990, 417:58-66.
44. Trautwein W, Hescheler J: Regulation of cardiac L-type calcium current by phosphorylation and G proteins. Annu Rev Physiol 1990, 52:257-274.
45. Le Grand B, Hatem S, Deroubaix E, Couetil J-P, Coraboeur E: Calcium current depression in isolated human atrial myocytes after cessation of chronic treatment with calcium antagonists. Circ Res 1991, 69:292-300.
46. Tsien RW, Bean BP, Hess P, Lansman JB, Nilius B, Nowycky MC: Mechanism of calcium channel modulation by ß-adrenergic agents and dihydropyridine calcium antagonists. J Mol Cell Cardiol 1986, 18:691-710.
47. Marban E, O'Rourke B: Calcium channels: structure, function, and regulation. In Cardiac Electrophysiology: From Cell to Bedside. Second Edition. Edited by Zipes DP, Jalife J. Philadelphia, PA: WB Saunders Co.; 1995:11-21.
48. January CT, Cunningham PM, Zhou Z: Pharmacology of L- and T-type calcium channels in the heart. In Cardiac Electrophysiology: From Cell to Bedside. Second Edition. Edited by Zipes DP, Jalife J. Philadelphia, PA: WB Saunders Co.; 1995:269-277.
49. 2+ currents in single canine Purkinje cells. Circ Res 1989, 65:1735-1750.
50. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993, 73:777-782.